Langerhans cell histiocytosis overview: Difference between revisions
No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Langerhans cell histiocytosis}} | {{Langerhans cell histiocytosis}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{NM}} | ||
==Overview== | ==Overview== | ||
Revision as of 00:18, 15 December 2015
|
Langerhans cell histiocytosis Microchapters |
|
Differentiating Langerhans cell histiocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Langerhans cell histiocytosis overview On the Web |
|
American Roentgen Ray Society Images of Langerhans cell histiocytosis overview |
|
Directions to Hospitals Treating Langerhans cell histiocytosis |
|
Risk calculators and risk factors for Langerhans cell histiocytosis overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Langerhans Cell Histiocytosis (LCH) is a rare disease involving clonal proliferation of langerhans cells, abnormal cells deriving from bone marrow and capable of migrating from skin to lymph nodes. Clinically, its manifestations range from isolated bone lesions to multisystemic disease.
The disease is part of a group of clinical syndromes called histiocytoses, which are characterized by an abnormal proliferation of histiocytes (an archaic term for dendritic cells and macrophages). These diseases are related to other forms of abnormal proliferation of white blood cells, such as leukemias and lymphomas.
Langerhans Cell Histiocytosis used to be called histiocytosis X, until it was renamed in 1985 by the Histiocyte society[1]